Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1Phase 1 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Dermatologic 2

Conditions

Prostatic Neoplasms 240Lymphoma 178Lymphoma, Large B-Cell, Diffuse 172Precursor Cell Lymphoblastic Leukemia-Lymphoma 87Lymphoma, Follicular 79Lymphoma, Non-Hodgkin 73Burkitt Lymphoma 66Multiple Myeloma 64Leukemia 57Hodgkin Disease 45Lymphoma, Mantle-Cell 41Neoplasms 34Lymphoma, T-Cell, Peripheral 31Lymphoma, B-Cell 30Lymphoma, B-Cell, Marginal Zone 28Lymphoma, Large-Cell, Anaplastic 26Neoplasm Metastasis 25Lymphoma, Large-Cell, Immunoblastic 24Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 22Leukemia, Lymphocytic, Chronic, B-Cell 22Neoplasms, Plasma Cell 21Recurrence 20Immunoblastic Lymphadenopathy 15Dendritic Cell Sarcoma, Interdigitating 15Lymphoma, T-Cell 14Leukemia, Biphenotypic, Acute 10Waldenstrom Macroglobulinemia 9Blast Crisis 9Primary Myelofibrosis 8Myelodysplastic Syndromes 8

Interventions

fludarabine phosphate 29Etoposide 26pegaspargase 24Peripheral Blood Stem Cell Transplantation 23Cyclophosphamide 23Whole-Body Irradiation 21Mycophenolic Acid 21Gemcitabine 19Busulfan 19Methotrexate 16Dexamethasone 16Tacrolimus 15Cyclosporine 14Antilymphocyte Serum 13Radiotherapy 12Oxaliplatin 10Rituximab 9Melphalan 8Asparaginase 8Doxorubicin 7Bortezomib 7spartalizumab 6Vorinostat 6Lenalidomide 6Flow Cytometry 6tislelizumab 5Vincristine 5Therapeutics 5Methylprednisolone 5Everolimus 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Lymphoma, Extranodal NK-T-Cell × Prednisone × Clear all
NCT00069238 2022-02-24

Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
31 enrolled 12 charts
Lymphoid

Lymphoma, Lymphoma, T-Cell, Lymphoma, Extranodal NK-T-Cell

NCT01445535 2021-11-03

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled 18 charts
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT02359162 2018-05-09

Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage

Sun Yat-sen University

Phase 3 Terminated
50 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT00513188 2016-12-15

Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma

University of Miami

Phase NA Withdrawn
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡